| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-138 |
Sentence |
denotes |
Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation. |
| T1 |
0-138 |
Sentence |
denotes |
Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation. |
| TextSentencer_T2 |
139-220 |
Sentence |
denotes |
Mutations in KCNJ11 cause majority of cases of permanent neonatal diabetes (PND). |
| T2 |
139-220 |
Sentence |
denotes |
Mutations in KCNJ11 cause majority of cases of permanent neonatal diabetes (PND). |
| TextSentencer_T3 |
221-350 |
Sentence |
denotes |
Multiple reports of PND with successful transitioning to oral sulfonylurea had been reported except for those with DEND syndrome. |
| T3 |
221-350 |
Sentence |
denotes |
Multiple reports of PND with successful transitioning to oral sulfonylurea had been reported except for those with DEND syndrome. |
| TextSentencer_T4 |
351-455 |
Sentence |
denotes |
This case report highlights a case of successful sulfonylurea treatment in a patient with DEND syndrome. |
| T4 |
351-455 |
Sentence |
denotes |
This case report highlights a case of successful sulfonylurea treatment in a patient with DEND syndrome. |